NGEN · Nervgen Pharma Corp.
$1.59
-0.02 (-1.24%)
At close · Jul 29
Market Cap
$171.32M
Shares
106.41M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$1.59
Open$1.62
Day$1.58–1.65
52W$1.58–6.30
Avg vol 30d805K
Short int4.5M · 4.2% float · 5.2d
Short vol70%
DataJan 2020–Jul 2026
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
Equibles Rating
blended score · not investment adviceOverall
Strong Sell
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Limited
Quant / Vol
Very High
Market backdrop
VIX 20.7 · elevated
Equity put/call 0.61
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−54%
below
Price vs 50-day avg
−22%
below
RSI (14)
32
neutral
MACD trend
Positive
52-week position
0%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−23%
trailing
6-month return
−62%
trailing
YTD return
−72%
this year
Relative strength
−69%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $2 › 200d $3 — 200d above 50d
Institutional flow
Accumulating
12 of 45 funds reported for Jun 30 · net +42.4K sh shares · +2 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
4.24% of float · ▲ +11.3% MoM · 5.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
45 holders — near 5-yr high, broad support
Squeeze score
64
elevated · 0–100
Fundamentals
Not enough data for a confident read.
Quant / Vol
risk profile
Volatility
89%
annualized · 1-yr
Max drawdown
−73%
past year
ATR
8.0%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−54%
Bearish
Price vs 50-day avg
−22%
Bearish
RSI (14)
32
Neutral
MACD trend
Positive
Bullish
52-week position
0%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $2 › 200d $3 — 200d above 50d
Institutional flow
Accumulating
12 of 45 funds reported for Jun 30 · net +42.4K sh shares · +2 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
4.24% of float · ▲ +11.3% MoM · 5.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
45 holders — near 5-yr high, broad support
Price context
position in its 52-week range
52-wk low $2
Now $2 · 0%
52-wk high $6
vs 200-day avg -54%
vs 50-day avg -22%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
NGEN
this stock
Nervgen Pharma Corp.
|
$171.32M | -71.6% | — | — | 4.2% |
|
ONC
BeOne Medicines Ltd.
|
$472.90B | +7.7% | +22179.2% | 962.4 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$124.46B | +6.6% | +46.2% | 29.1 | 2.0% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$72.88B | -9.8% | +20.8% | 17.0 | 3.3% |
|
ARGX
Argenx SE
|
$54.57B | +4.9% | — | — | 2.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| NGEN | -7.6% | -22.8% | -62.4% | -22.8% | -71.6% |
| SPY | -2.4% | -2.3% | +6.3% | -2.3% | +7.0% |
| vs SPY | -5.2% | -20.5% | -68.7% | -20.5% | -78.6% |